Big Pharma Fails 50% of the Time in Phase Three. AI Can Fix That | Vin Singh, BullFrog AI

Bullfrog AI addresses the high failure rates in late-stage clinical development by leveraging artificial intelligence to de-risk drug discovery and development. The platform employs three core solutions: BF-PREP, which structures messy biomedical data; BF-LEAP, an analytics engine utilizing causal AI to identify root-cause disease drivers; and BF-ARENAS, which ranks potential drug targets to improve decision-making. By applying these tools to complex datasets, such as the Lieber Institute’s collection of neuropsychiatric brain tissue, the company has identified novel genetic drivers for depression, bipolar disorder, and schizophrenia. CEO Vin Singh emphasizes that the company’s goal is to provide precision medicine insights that enable Big Pharma to select more viable drug targets, ultimately reducing the time and capital required to bring effective treatments to market.